Abstract:Background: Metabolic reprogramming is a characteristic of tumor cells and is considered a potential therapeutic target. Even under aerobic conditions, tumor cells use glycolysis to produce energy, a phenomenon called the "Warburg effect". Pyruvate dehydrogenase kinase 1 (PDK1) is a key factor linking glycolysis and the tricarboxylic acid cycle. Dichloroacetic acid (DCA) reverses the Warburg effect by inhibition of PDKI to switch cytoplasmic glucose metabolism to mitochondrial oxidative phosphorylation (OXPHOS).Methods: Cell viability was examined using a standard MTT assay. Glucose consumption and L-lactate production were measured using commercial colorimetric kits, and intracellular lactate dehydrogenase (LDH) activity was evaluated using cell lysates and an LDH Quantification Kit. Real-time PC R was used to detect the expression of related genes. The production of total ROS was evaluated by staining with dichlorofluorescin diacetate.Results: Comparison of various aspects of glucose metabolism, such as expression of key enzymes in glycolysis, lactate production, glucose consumption, mitochondrial oxygen consumption rate, and citric acid production, revealed that A2780/DDP cells were primarily dependent on glycolysis whereas A2780 cells were primarily dependent on mitochondrial OXPHOS. Mitochondrial uncoupling protein 2 (UCP2) protects against mitochondrial ROS while allowing energy metabolism to switch to glycolysis. Treatment of A2780 cells with various concentrations of DCA resulted in decreased expression of UCP2, a metabolic switch from glycolysis to mitochondrial OXPHOS, and an increase in oxidative stress induced by ROS. These effects were not observed in A2780/DDP cells with higher UCP2 expression suggesting that UCP2 might induce changes in mitochondrial functions that result in different sensitivities to DCA.Conclusion: Our results show that a drug targeting tumor metabolic changes affects almost the entire process of glucose metabolism. Thus, it is necessary to comprehensively determine tumor metabolic functions to facilitate individualized antitumor therapy.

Restricting tumor lactic acid metabolism using dichloroacetate improves T cell functions

Lithium carbonate revitalizes tumor-reactive CD8 + T cells by shunting lactic acid into mitochondria

Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity

Dichloroacetic Acid Upregulates Apoptosis Of Ovarian Cancer Cells By Regulating Mitochondrial Function

Tumor lactic acid: a potential target for cancer therapy

From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

Targeting the Lactic Acid Metabolic Pathway for Antitumor Therapy

Dichloroacetate Enhances the Antitumor Efficacy of Chemotherapeutic Agents Via Inhibiting Autophagy in Non-Small-cell Lung Cancer

Effects of Dichloroacetate on the Activation of the Mitochondrial Pathway in C6 Cells in Vitro

Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells

Lactate Limits T Cell Proliferation via the NAD(H) Redox State

Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy

Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity

Tumor‐Selective Nano‐Dispatcher Enforced Cancer Immunotherapeutic Effects via Regulating Lactate Metabolism and Activating Toll‐Like Receptors

Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma

Tumor Microenvironment: Lactic Acid Promotes Tumor Development

Downregulation of Membrane Trafficking Proteins and Lactate Conditioning Determine Loss of Dendritic Cell Function in Lung Cancer

Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling

Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism